For example, patients with non-functional (mutated) BRCA1 or BRCA2, associated with hereditary breast and ovarian cancer, respond better to platinum chemotherapy owing to an increased sensitivity to DNA damage-induced cell death (Cass et al, 2003). Here, BRCA2 is linked to ovarian cancer.